报价延迟最少15分钟:2025/09/15 09:03 EDT
盘前时段
|
||||
|
2.18 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
--
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-11.65/-21.39
|
|
企业价值
4.93M
|
| 资产负债 |
|
每股账面净值
3.51
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
825.79K
|
|
每股收益
2.07
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/09/15 09:03 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids. |
